drugset / Trial / NCT04699461
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to evaluate the efficacy of single agent loncastuximab tesirine compared to idelalisib in participants with relapsed or refractory follicular lymphoma.
Timeline
- Start
- 2021-11-04
- Primary completion
- 2022-11-25
- Completion
- 2022-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Idelalisib | Small molecule | 150 mg | Oral |
| Subject | Loncastuximab Tesirine | Other / unclassified | 75 ug/kg | Intravenous |